Purpose of this document
This document is not NICE guidance. It is a summary of the external assessment group's model and assumptions on renal cell carcinoma, discussed by NICE's technology appraisal committee B. This report is the basis of NICE's technology appraisal guidance on cabozatinib with nivolumab for untreated advanced renal cell carcinoma.